Hi ,

Welcome back to this month’s newsletter, bringing all the latest trends, news, insights, and more into the synbio for the human health industry. 

It was an honor and a privilege to host synbio and pharma leaders last month at SynBioBeta’s Global Synthetic Biology Conference. They took the stage together to share their experience, the specific challenges we face in achieving the next generation of therapies, and their inspiring vision for the future of medicine. 

This edition is brought to you by leading cell reprogramming company, bit.bio. Here we dive deep into the key insights and strategies for how synbio and Pharma can communicate and become more effective partners.

How Do We Unite Synbio and Pharma? Insights from SynBioBeta 2023

The synbio community often talks about the industry’s lofty promises to solve many of the world’s biggest problems. And we should talk about that. The youthful willingness to take big risks and chase moonshots is a wonderful and unique characteristic of our community.

But how are we actually doing in bringing synbio into our day-to-day lives, especially when it comes to our health?

Until recently, the answer has been "pretty poorly." Change has come sporadically. And though CAR-T cell therapies and mRNA vaccines have been tremendous breakthroughs, those technologies are far from ubiquitous. As I’ve written about previously, synbio for human health demands a full-stack approach. At SynBioBeta 2023, we got our first real look at that stack coming to life.

Read the full article here →

News from the Community

• SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy

• ARPA-H launches its first research program to solve treatment challenges in osteoarthritis by developing new ways to help the human body regenerate its own joints

• Synlogic announces Phase III global clinical trial for phenylketonuria (PKU) treatment

• Human cell reprogramming company bit.bio launches custom disease models from drug discovery and development 

• Deep dive with Antheia: Engineered yeast could help end drug shortages and transform pharma supply chains

• Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

• ElevateBio raises $401 million Series D in year's largest biotech VC deal

• Touchlight completes expansion, creating one of the world’s largest DNA manufacturing facilities in London, UK

• Minutia receives award from JDRF to further develop real-time monitoring platform for cell therapies

Have news or comments you’d like to share? Reach out to us at humanhealth@synbiobeta.com

That’s all from us this month but we’ll be back next month with new insights, opinions, and spotlights on the breakthroughs of synbio for human health.

Until next time,
Fiona

Fiona Mischel
Director, Human Health Content and Innovation

View in Browser »

SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549

info@synbiobeta.com

If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences